Literature DB >> 16791584

Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern?

Laurent Azoulay1, Driss Oraichi, Anick Bérard.   

Abstract

OBJECTIVES: To (1) describe the patterns and trends of isotretinoin utilization between 1984 and 2003, (2) describe the characteristics of isotretinoin users within that same time period, (3) identify and quantify predictors of isotretinoin use, and (4) describe the impact of guidelines on isotretinoin utilization between 1984 and 2003.
METHODS: Using the Régie de l'Assurance Maladie du Québec (healthcare utilization, medications) and Med-Echo (hospitalizations) administrative databases, we conducted a descriptive study on a population-based sample of first-time isotretinoin users from 1984 to 2003. We determined the characteristics of these users, predictors of an isotretinoin treatment >or=20 weeks, and impact of guidelines on the number of new isotretinoin users. Guidelines included the implementation of the Pregnancy Prevention Program (PPP - 1988) and the Dear Healthcare Professional Letter regarding possible psychiatric risks issued to Canadian physicians (DHPL - 2001).
RESULTS: Mean (SD) age was 23.9 (7.6) years; 50% males, 52% welfare recipients, 77% urban dwellers, and 55% of prescriptions were written by dermatologists. Sixty-four percent of patients did not receive any anti-acne medications in the 12 months prior to receiving isotretinoin. Thirty-five percent of patients had an isotretinoin treatment >or=20 weeks suggested by product guidelines. The odds ratio of having a treatment >or=20 weeks significantly increased after the implementation of the PPP and other guidelines. There was no statistically significant decrease in the number of new isotretinoin users following the implementation of the PPP and DHPL.
CONCLUSION: These data suggest inappropriate isotretinoin utilization, even more so after guidelines were promulgated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16791584     DOI: 10.1007/s00228-006-0151-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment.

Authors:  R Tamblyn; T Reid; N Mayo; P McLeod; M Churchill-Smith
Journal:  J Clin Epidemiol       Date:  2000-02       Impact factor: 6.437

Review 2.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

3.  Acute depression from isotretinoin.

Authors:  S Gatti; F Serri
Journal:  J Am Acad Dermatol       Date:  1991-07       Impact factor: 11.527

4.  Isotretinoin therapy for acne: a population-based study.

Authors:  D J Hogan; L M Strand; P R Lane
Journal:  CMAJ       Date:  1988-01-01       Impact factor: 8.262

5.  Teratogenicity of isotretinoin.

Authors:  F W Rosa
Journal:  Lancet       Date:  1983-08-27       Impact factor: 79.321

6.  Accutane Roche: risk of teratogenic effects.

Authors:  D P Zarowny
Journal:  Can Med Assoc J       Date:  1984-08-15       Impact factor: 8.262

7.  Are there racial and sex differences in the use of oral isotretinoin for acne management in the United States?

Authors:  Alan B Fleischer; Joanne K Simpson; Amy McMichael; Steven R Feldman
Journal:  J Am Acad Dermatol       Date:  2003-10       Impact factor: 11.527

Review 8.  Uses and complications of isotretinoin therapy.

Authors:  C N Ellis; K J Krach
Journal:  J Am Acad Dermatol       Date:  2001-11       Impact factor: 11.527

9.  Oral isotretinoin: an analysis of its utilization in a managed care organization.

Authors:  Kristina Chen; T Jeffrey White; Michael Juzba; Eunice Chang
Journal:  J Manag Care Pharm       Date:  2002 Jul-Aug

10.  A pregnancy-prevention program in women of childbearing age receiving isotretinoin.

Authors:  A A Mitchell; C M Van Bennekom; C Louik
Journal:  N Engl J Med       Date:  1995-07-13       Impact factor: 91.245

View more
  12 in total

Review 1.  Impact of safety-related regulatory action on clinical practice: a systematic review.

Authors:  Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  Isotretinoin use and the risk of inflammatory bowel disease: a case-control study.

Authors:  Seth D Crockett; Carol Q Porter; Christopher F Martin; Robert S Sandler; Michael D Kappelman
Journal:  Am J Gastroenterol       Date:  2010-03-30       Impact factor: 10.864

3.  Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data.

Authors:  Martina Teichert; Loes E Visser; Mark Dufour; Eline Rodenburg; Sabine M J M Straus; Peter A G M De Smet; Bruno H Ch Stricker
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

4.  Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective.

Authors:  Anick Bérard; Laurent Azoulay; Gideon Koren; Lucie Blais; Sylvie Perreault; Driss Oraichi
Journal:  Br J Clin Pharmacol       Date:  2007-02       Impact factor: 4.335

5.  Concerns and awareness of acne patients about isotretinoin in qassim region of saudi arabia.

Authors:  Mana Al-Harbi
Journal:  Int J Health Sci (Qassim)       Date:  2010-01

6.  Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy.

Authors:  David Henry; Colin Dormuth; Brandace Winquist; Greg Carney; Shawn Bugden; Gary Teare; Linda E Lévesque; Anick Bérard; J Michael Paterson; Robert W Platt
Journal:  CMAJ       Date:  2016-04-25       Impact factor: 8.262

7.  The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin.

Authors:  Kanika Anand; Ingrid Sketris; Ying Zhang; Adrian Levy; John-Michael Gamble
Journal:  Drugs Real World Outcomes       Date:  2017-12

8.  Isotretinoin exposure in pregnant women in Korea.

Authors:  Nae Ry Kim; So Ra Yoon; June Seek Choi; Hyun Kyong Ahn; So-Young Lee; Dal Soo Hong; Jeong Sup Yun; Seong Yeon Hong; Yoon Ha Kim; Jung Yeol Han
Journal:  Obstet Gynecol Sci       Date:  2018-10-12

Review 9.  Isotretinoin; A review on the Utilization Pattern in Pregnancy.

Authors:  Sajad Khiali; Afshin Gharekhani; Taher Entezari-Maleki
Journal:  Adv Pharm Bull       Date:  2018-08-29

10.  Using Natural Language Processing to Examine the Uptake, Content, and Readability of Media Coverage of a Pan-Canadian Drug Safety Research Project: Cross-Sectional Observational Study.

Authors:  Hossein Mohammadhassanzadeh; Ingrid Sketris; Robyn Traynor; Susan Alexander; Brandace Winquist; Samuel Alan Stewart
Journal:  JMIR Form Res       Date:  2020-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.